Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN968822 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Titin-Cap (Telethonin) (TCAP) (AA 1-167) antibody
- Antibody type
- Monoclonal
- Antigen
- Mouse Telethonin
- Description
- Purified from tissue culture supernatant or ascites by affinity chromatography.
- Reactivity
- Mouse
- Host
- Mouse
- Epitope
- AA 1-167
- Isotype
- IgG
- Antibody clone number
- FB11
- Vial size
- 50 μg
- Concentration
- 250 μg/ml
- Storage
- -20°C
Submitted references Early and selective disappearance of telethonin protein from the sarcomere in neurogenic atrophy.
Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin.
The novel sarcomeric protein telethonin exhibits developmental and functional regulation.
Telethonin, a novel sarcomeric protein of heart and skeletal muscle.
Schröder R, Reimann J, Iakovenko A, Mues A, Bönnemann CG, Matten J, Gautel M
Journal of muscle research and cell motility 2001;22(3):259-64
Journal of muscle research and cell motility 2001;22(3):259-64
Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin.
Moreira ES, Wiltshire TJ, Faulkner G, Nilforoushan A, Vainzof M, Suzuki OT, Valle G, Reeves R, Zatz M, Passos-Bueno MR, Jenne DE
Nature genetics 2000 Feb;24(2):163-6
Nature genetics 2000 Feb;24(2):163-6
The novel sarcomeric protein telethonin exhibits developmental and functional regulation.
Mason P, Bayol S, Loughna PT
Biochemical and biophysical research communications 1999 Apr 21;257(3):699-703
Biochemical and biophysical research communications 1999 Apr 21;257(3):699-703
Telethonin, a novel sarcomeric protein of heart and skeletal muscle.
Valle G, Faulkner G, De Antoni A, Pacchioni B, Pallavicini A, Pandolfo D, Tiso N, Toppo S, Trevisan S, Lanfranchi G
FEBS letters 1997 Sep 29;415(2):163-8
FEBS letters 1997 Sep 29;415(2):163-8
No comments: Submit comment
No validations: Submit validation data